Indaptus Therapeutics Inc

NASDAQ:INDPUnited States

Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.

Contact Information

Headquarters

3 Columbus Circle, 15Th FloorNEW YORK, NY, United States 10019

Phone

646-427-2727

Fax

---

Executives

Independent Non-Executive Chairman of the Board

Roger Pomerantz

Chief Executive Officer, Director

Jeffrey Meckler

Chief Financial Officer, Treasurer, Secretary

Nir Sassi

Chief Operating Officer

Walt Linscott

Chief Scientific Officer, Director

Michael Newman